Garadacimab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Factor XII in Thrombosis and Thromboinflammation: From Molecular Biology to Clinical Translation.
Journal: International journal of molecular sciences
Published: February 26, 2026
Response to "Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema".
Journal: Drugs in R&D
Published: January 12, 2026
Donidalorsen (Dawnzera) for prevention of hereditary angioedema attacks.
Journal: The Medical letter on drugs and therapeutics
Published: January 08, 2026
Garadacimab-gxii-A Novel Prophylactic Treatment for Hereditary Angioedema: A Drug Review.
Journal: The Annals of pharmacotherapy
Published: January 07, 2026
Garadacimab (Andembry) for hereditary angioedema prophylaxis.
Journal: The Medical letter on drugs and therapeutics
Published: November 05, 2025
Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema.
Journal: Journal of comparative effectiveness research
Published: July 10, 2025
Pharmacological characteristics and clinical trial results of garadacimab (anti-activated factor XII monoclonal antibody) for long-term prophylaxis of hereditary angioedema
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: July 09, 2025
Comment on: "A national survey of four decades of hereditary angioedema prophylaxis" - The emerging role of Garadacimab.
Journal: Clinical immunology (Orlando, Fla.)
Published: June 19, 2025
The potential of factor XII inhibitors in preventing hereditary angioedema attacks.
Journal: Expert opinion on biological therapy
Published: May 24, 2025
Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema.
Journal: Allergy and asthma proceedings
Published: May 17, 2025
Last Updated: 04/28/2026